One important example is ibrutinib, a small molecule designed to target Bruton’s tyrosine kinase (BTK) that was successfully used in clinical practice for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom’s macroglobulinemia. This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.